Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Serum α2-HS glycoprotein concentration in patients with hematological malignancies

A follow-up study

Summary

We observed significantly reduced serum α2-HS glycoprotein concentrations in patients with acute lymphocytic, acute nonlymphocytic, chronic granulocytic and chronic myelomonocytic leukemias, Hodgkin's and non-Hodgkin's lymphomas, myelofibrosis, and multiple myeloma, but not in patients with chronic lymphocytic leukemia and polycythemia vera, as compared with healthy controls. We followed the serum level of the protein for 18 months. Patients with infectious complications, those receiving cytostatic treatment, and those in the preterminal period had further reduced serum α2-HS glycoprotein levels. The reduction of serum α2-HS glycoprotein concentration was primarily due to decreased production caused by infiltration of the liver, a hepatotoxic effect of cytostatic treatment, and, to a lesser degree, to increased consumption. We found statistically significant negative correlations between serum α2-HS glycoprotein concentration and erythrocyte sedimentation rate, serum aspartate aminotransferase and alkaline phosphatase activities, and IgG and IgM concentrations. The determination of the α2-HS glycoprotein concentration is useful for the assessment and follow-up of the clinical status and therapy of patients with hematological malignancies and also has prognostic significance.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Asthon BA, Smith R (1980) Plasma α2HS-glycoprotein concentration in Paget's disease of bone: its possible significance. Clin Sci 58: 435–438

  2. 2.

    Asthon BA, Hohling HJ, Triffitt JT (1976) Plasma proteins present in human cortical bone: enrichment of the α2HS-glycoprotein. Calcif Tissue Res 22: 27–33

  3. 3.

    Baskies AM, Chretien PB, Weiss JF, Makuch RW, Beveridge RA, Catalona ABWJ, Spiegel HE (1980) Serum glycoproteins in cancer patients: first report of correlations with in vitro and in vivo parameters of cellular immunity. Cancer 45: 3050–3060

  4. 4.

    Bradley WP, Blasco AP, Weiss JF, Alexander JC jr, Silverman NA, Chretien PB (1977) Correlations among serum proteinbound carbohydrates, serum glycoproteins, lymphocyte reactivity, and tumor burden in cancer patients. Cancer 40: 2264–2272

  5. 5.

    Colclasure GC, Lloyd WS, Lamkin M, Gonnermann W, Troxler RF, Offner GD, Burgi W, Schmid K, Nimberg RB (1988) Human serum α2HS glycoprotein modulates in vitro bone resorption. J Clin Endocrinol Metab 66: 187–192

  6. 6.

    Crawford JC (1984) α2-HS glycoprotein in the hypercalcemia of multiple myeloma. Br J Cancer 49: 813–815

  7. 7.

    Daveau M, Davrinche C, Julen N, Hiron M, Arnaud P, Lebreton JP (1988) The synthesis of human α2-HS glycoprotein is down-regulated by cytokines in hepatoma HepG2 cells. FEBS Lett 241: 191–194

  8. 8.

    Dickson IR, Poole AR, Veis A (1975) Localisation of plasma α2HS-glycoprotein in mineralising human bone. Nature 256: 430–432

  9. 9.

    Jakab L, Jakab LA, Kalabay L, Pozsonyi T, Cseh K (1991) The effect of the α2HS-glycoprotein on the mitogen-induced lymphocyte blastic transformation and the IL-2 production. Acta Physiol Acad Sci Hung 77:25–31

  10. 10.

    Jezequel M, Seta NS, Corbic MM, Feger JM, Durand GM (1988) Modifications of concanavalin A patterns of α1-acid glycoprotein and α2HS-glycoprotein in alcoholic liver disease. Clin Chim Acta 176: 49–58

  11. 11.

    Kalabay L, Cseh K, Pozsonyi T, Benedek Sz, Fekete S, Jakab LA, Jakab L (1990) Serum α2HS-glycoprotein concentration in patients with acute and chronic leukemias. Blut 61: 175

  12. 12.

    Kalabay L, Jakab L, Cseh K, Pozsonyi T, Jakab LA (1990) Correlation between serum α2HS-glycoprotein concentration and conventional laboratory parameters in systemic lupus erythematosus. Acta Medica Hung 47: 53–64

  13. 13.

    Kishore BK, Gejyo F, Arakawa M (1983) α2HS-glycoprotein in the serum and urine of patients with renal diseases. Postgrad Med J 59: 304–307

  14. 14.

    Laurell CB (1966) Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 15: 45–52

  15. 15.

    Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G (1979) Serum concentration of human α2HS-glycoprotein during the inflammatory process. J Clin Invest 64: 1118–1129

  16. 16.

    Leon SA, Shapiro B, Skalroff DM, Yaros MJ (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37: 646–650

  17. 17.

    Lewis JG, Andre CM (1978) A serum DNA-binding protein absent in malignant disease. FEBS Lett 92: 211–213

  18. 18.

    Lewis JG, Andre CM (1991) Enhancement of human monocyte phagocytic function by α2HS-glycoprotein. Immunology 42: 481–487

  19. 19.

    Lewis JG, Andre CM (1984) The effect of α2HS-glycoprotein on lymphocyte reactivity to phytohemagglutinin. Immunol Commun 13: 35–47

  20. 20.

    Lewis JG, Crosier PS, Andre CM (1982) α2HS-glycoprotein binds to lymphocytes transformed by Epstein-Barr virus. FEBS Lett 138: 37–39

  21. 21.

    Lipson SD, Chretien PB, Makuch RW, Kenady DE, Cohen MH (1979) Thymosin immunotherapy in patients with small cell carcinoma of the lung: Correlation of in vitro studies with clinical course. Cancer 43: 863–870

  22. 22.

    Malone JD, Richards M (1987) α2HS-glycoprotein is chemotactic for mononuclear phagocytes. J Cell Physiol 132: 118–125

  23. 23.

    Malone JD, Teitelbaum SL, Griffin GL, Senior RM, Kahn AJ (1982) Recruitment of osteoclast precursors by purified bone matrix constituents. J Cell Biol 92: 227–230

  24. 24.

    Mancini G, Carbonara AO, Heremans JF (1965) Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 2: 235–254

  25. 25.

    Oss van CJ, Gilman CF, Bronson PM, Border JR (1974) Opsonic properties of human serum α2HS-glycoprotein. Immunol Commun 3: 329–335

  26. 26.

    Oss van CJ, Bronson PM, Border JR (1975) Changes in the serum α-glycoprotein distribution in trauma patients. J Trauma 15: 451–455

  27. 27.

    Pavesi F, Merlini G, Epis R, Zorzoli I, Moratti R, Gorini M, Ascari E (1982) α2HS-glycoprotein in multiple myeloma. Haematologica (Pavia) 67: 845–852

  28. 28.

    Putnam WF (1960) The plasma proteins. Academic, New York

  29. 29.

    Richterich R, Colombo JP (1978) Klinische Chemie. Theorie, Praxis, Interpretation. Karger, Basel

  30. 30.

    Schelp FP, Thanangkul O, Supawan V, Pangpaew P (1980) α2HS-glycoprotein serum levels in protein-energy malnutrition. Br J Nutr 43: 381–385

  31. 31.

    Triffitt JT, Gebauer U, Asthon BA, Owen ME, Reynolds JJ (1976) Origin of plasma α2HS-glycoprotein and its accumulation in bone. Nature 262: 226–227

  32. 32.

    Wiedermann D, Wiedermann B, Cidl V, Koduskova V (1978) Individual serum proteins and acute-phase reactants in monoclonal immunoglobulinopathies. Neoplasma 25: 189–196

Download references

Author information

Correspondence to L. Kalabay.

Additional information

This work was supported by the Hungarian Academy of Sciences OTKA No. 161

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kalabay, L., Cseh, K., Benedek, S. et al. Serum α2-HS glycoprotein concentration in patients with hematological malignancies. Ann Hematol 63, 264–269 (1991). https://doi.org/10.1007/BF01698376

Download citation

Key words

  • α2- HS glycoprotein
  • Leukemias
  • Lymphomas
  • Myelofibrosis
  • Multiple myeloma
  • Polycythemia vera